Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D.L. Bowtell, Frances R. Balkwill, Steffen Böhm et al.|Nature reviews. Cancer|2015Cited by 1.4k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B. Daly, Mary A. Dwyer, Carolyn S. Menendez et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1.1k
Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian CancerTimothy R. Rebbeck, Saundra S. Buys, Nandita Mitra et al.|JAMA|2015Cited by 507
Gene Expression Profile of <i>BRCA</i>ness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian CancerPanagiotis A. Konstantinopoulos, Stephen A. Cannistra, Dimitrios Spentzos et al.|Journal of Clinical Oncology|2010Cited by 488
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian CancerSusan J. Ramus, Simon A. Gayther, Honglin Song et al.|JNCI Journal of the National Cancer Institute|2015Cited by 441